Quipt Home Medical Corp. announced its financial results for the third quarter of fiscal year 2025, ended June 30, 2025. The company reported a return to positive organic growth and achieved revenue stabilization across its business.
Total revenue for Q3 2025 was $58.3 million, an increase from the previous quarter's $57.38 million, but still a decrease from $60.1 million in Q3 2024. Adjusted EBITDA for the quarter was $13.7 million, maintaining a strong Adjusted EBITDA margin of 23.5%.
The company reported a net loss of $2.0 million, or $0.05 per diluted share, for Q3 2025, compared to a net loss of $0.9 million, or $0.02 per diluted share, in Q3 2024. Patients serviced were 147,000, and respiratory resupply setups/deliveries were 153,000.
Quipt highlighted the subsequent completion of the Ballad Health acquisition, which was announced on July 7, 2025. This transaction embeds Quipt directly into the discharge pathway of a prominent integrated health system, reinforcing its strategy of expanding through healthcare system partnerships.
Management expressed confidence in maximizing long-term shareholder value and stated that the structural improvements made over the past several quarters position the company for sustainable long-term growth. The company maintained a conservative balance sheet with a net debt to Adjusted EBITDA leverage ratio of 1.5 times.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.